A Phase II Randomized Trial of Lenalidomide (NSC # 703813, IND # 70116) in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
This purpose of this study is to compare the response rate of pediatric patients with recurrent, refractory or progressive juvenile pilocytic astrocytomas and optic pathway gliomas who are treated with lenalidomide. The study will compare the study participant¿s response to either high-dose or low-dose treatment plan. The treatment participants will received is based on chance or a randomization process. Regimen A is the low-dose (20 mg/m2/dose) lenalidomide, and Regimen B is the high-dose (115 mg/m2/dose) lenalidomide.
Back to Clinical Trials list